PAX-5 – the most sensitive and reliable biomarker for B-cell malignancies
Pax-5, or B-cell-specific activator protein, is a nuclear protein in the paired-box containing (PAX) family of transcription factors involved
in control of organ development and tissue differentiation.
Pax-5 staining is positive in most Hodgkin and B-cell non-Hodgkin lymphomas and also precursor B-cell lymphoblastic neoplasms. Plasma cell neoplasms, multiple myeloma and plasmablastic lymphomas, as well as T-cell lymphomas, are typically negative.
Pax-5 immunohistochemistry therefore has become a well accepted and valuable tool in diagnosis and subclassification of lymphomas.
MPG possesses and provides intellectual property rights to the use of Pax-5 directed probes, encompassing Pax(-5)-directed nucleic acid probes as well as anti-Pax-5-antibodies, as tumor-diagnostics. The IP was developed at the Max Planck Institute of biophysical chemistry in Göttingen by Prof. Gruss and co-workers.
US patent 5,747,250 was granted on May 5th 1998.
EP patent 0655926 was granted on Jan 28th 1998.
Competitiveness of Pax-5 based diagnostics in the field:
- most sensitive and reliable diagnostic biomarker to date
- background-free nuclear immunoreactivity achievable
- superior maintenance of expression over established B-cell markers (CD19, CD20, CD79a or alike)
- well suited to monitor patients post-rituximab treatment to unanimously detect CD20-negative B-cell lymphomas
The Pax-5 related intellectual property of Max Planck Society is available preferably for non-exclusive licensing.